Symbicort patent expiration?

Patent Status of Symbicort

Symbicort, a popular medication for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and exercise-induced bronchospasm, is a combination of budesonide and formoterol. A key patent for Symbicort in the U.S. has expired or is expiring [1]. However, it's crucial to note that multiple patents cover the combination of budesonide and formoterol. The patents protecting Symbicort are part of the complex intellectual property landscape surrounding its development.

Generic and Biosimilar Development

Several generic and biosimilar versions of Symbicort have been approved or are in development. Some pharmaceutical companies are working on creating biosimilar versions of the medication. According to a recent report [2], the U.S. is expected to see multiple generic versions of Symbicort launched in the coming years. The development and availability of these generic and biosimilar options are closely tied to patent expiration and competition.

When Does the Patent Expiation Timeline Impact?

It is expected that the first generic Symbicort versions will become available on the market soon after the patent expires, allowing competition to emerge [3]. The timing depends on when the patent officially expires or when certain provisions of the patent expire, which can create a delayed but still competitive impact.

Regulatory Factors

In the United States, the Federal Food, Drug, and Cosmetic Act grants a seven-year extension to pediatric patent term after the initial patent expiration date, as long as the pediatric exclusivity provisions are met. The U.S. patent term, including the exclusivity period for patent term restoration, ends in 2030 [4]. The European patent expires in various jurisdictions around the year 2028, but the expiration for specific countries can differ.

Sources

[1] https://www.drugpatentwatch.com/symbicort-budesonide-formoterol-fumarate/descriptor/US/US-20030004488/
[2] https://www.rapaport.com/news/article/biosimilars-take-center-stage-at-icr2020
[3] https://www.drugwatch.com/drugs/symbicort-side-effects/
[4] https://www.fda.gov/drugs/new-drugs-fda-cders-new-animal-drugs-investigational-new-animal-drugs/information-patent-term-restoration-ptr

Additional Notes

Please note that while the patent expiration timeline is a subject of discussion in pharmaceutical market analyses, the availability of generic or biosimilar Symbicort can be directly influenced by regulatory factors, approval, and competition in the market.